Clinical Trial Update: Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of CEP-9722 (PARP inhibitor) in solid tumors was terminated; results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• CEP-9722

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Solid Tumors | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-01-30